ReportsnReports – Point of Care Diagnostic Testing World Markets
Upcoming SlideShare
Loading in...5
×
 

ReportsnReports – Point of Care Diagnostic Testing World Markets

on

  • 2,299 views

Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or ...

Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.

Statistics

Views

Total Views
2,299
Slideshare-icon Views on SlideShare
2,299
Embed Views
0

Actions

Likes
0
Downloads
38
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    ReportsnReports – Point of Care Diagnostic Testing World Markets ReportsnReports – Point of Care Diagnostic Testing World Markets Document Transcript

    • Point of Care Diagnostic Testing World MarketsPoint of care testing (POCT) enables rapid diagnostic tests to be performed while the patientis at the point of care facility where results can be obtained immediately, rather thanwaiting hours or even days for outside lab results to arrive. Point of care testing covers:blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapidcardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancytesting, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics,infectious disease testing and cholesterol screening.Buy Now: Care Diagnostic Testing World MarketsBrowse All: Latest Market Research ReportsThis TriMark Publications report describes latest developments in the point of care testingmarket segment. It examines clinical instruments, devices and reagents and supplies asutilized in near-patient environments like hospital emergency rooms, critical care units,clinics and doctor’s offices. The study defines the dollar volume of point of care sales andmakes five year projections–both in the U.S. and worldwide–including Europe, Asia andLatin America. It also examines in detail the point of care sector for 25 individual countrymarkets. A detailed summary of all important instruments in each clinical market isprovided with emphasis on newly introduced products. Moreover, parallel areas where rapiddetection is important using hand-held devices such as rapid detection of food pathogensand infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) arediscussed. Growth moderators and developing trends in point of care applications, as well astechnology platform innovations and connectivity questions are examined in detail.The report surveys almost all of the companies known to be marketing, manufacturing ordeveloping instruments and reagents for the point of care market in the U.S. and worldwide.Each company is discussed in depth, with a section on its history, product lines, businessand marketing analysis, and a subjective commentary of the company’s market position.Detailed tables and charts with sales forecasts and market data are also included.Table of Contents1. Overview1.1 About this Report1.2 Scope of the Report1.3 Objectives1.4 Methodology1.5 Executive Summary2. Overview of Diagnostic Testing Point of Care2.1 Point of Care Testing Sites2.2 Point of Care Market Structure2.3 New Directions in Clinical IVD Testing
    • 3. POCT and Rapid Testing Market Analysis: Size, Background Analysis, Growth,Share and Competitors3.1 Global POCT Market3.2 U.S. POCT Market3.3 European POCT Market3.3.1 German POCT Diagnostic Market3.3.2 U.K. POCT Diagnostic Market3.3.2.1 U.K. POCT Market Statistics3.3.2.2 U.K. Competitive Analysis3.3.2.3 U.K. Market Access3.3.3 French POCT Diagnostic Market3.3.4 Italian POCT Diagnostic Market3.3.5 Spanish POCT Diagnostic Market3.3.6 Scandinavian POCT Diagnostic Market3.3.7 Swedish POCT Diagnostic Market3.3.8 Finnish POCT Diagnostic Market3.3.9 Norwegian POCT Diagnostic Market3.3.10 Swiss POCT Diagnostic Market3.3.11 Dutch POCT Diagnostic Market3.3.12 Belgian POCT Diagnostic Market3.3.13 Portuguese POCT Diagnostic Market3.3.14 Austrian POCT Diagnostic Market3.3.15 Greek POCT Diagnostic Market3.3.16 Polish POCT Diagnostic Market3.3.17 Czech Republic POCT Diagnostic Market3.3.18 Turkish POCT Diagnostic Market3.4 Asian POCT Markets3.4.1 Japanese POCT Diagnostic Market3.4.2 Indian POCT Diagnostic Market3.4.3 Chinese POCT Diagnostic Market3.5 Rest of the World POCT Market3.5.1 Canadian POCT Diagnostic Market3.5.2 Brazilian POCT Diagnostic Market3.5.3 Australian POCT Diagnostic Market3.6 Overview of Asian Healthcare Market3.6.1 Singapore3.6.2 Malaysia3.6.3 Thailand3.6.4 Indonesia3.6.5 Philippines3.6.6 South Korea3.6.7 Taiwan4. POCT Individual Markets4.1 Glucose Testing4.2 POCT Individual Market Sectors, Size, Growth Rates and Competitors4.2.1 World Market Revenue and Forecasts4.2.2 Professional Glucose Testing Market for POCT U.S. Revenue and Forecasts during2001-2012
    • 4.2.3 European Market4.2.4 Market Share4.2.5 Alternate Glucose Monitoring Products4.2.6 HbA1c POCT4.2.7 Market Challenges and Strategic Recommendations4.2.7.1 Market Drivers and Restraints4.2.7.1.1 Market Drivers4.2.7.1.2 Market Restraints4.2.7.2 Point of Care Glucose Testing Assay Market and Technology Trends4.2.7.2.1 Point of Care Glucose Testing Assay Market Trends4.2.7.2.2 Point of Care Glucose Testing Assay Technology Trends4.2.7.2.3 Point of Care Glucose Testing Assay Strategic Recommendations4.3 Blood Gas and Electrolytes4.3.1 Whole Blood Lactate4.3.2 Creatinine4.4 Rapid Coagulation Tests4.4.1 World POCT Coagulation Market4.4.2 U.S. Coagulation Market4.4.3 European Coagulation Market4.4.4 Trends in POCT Coagulation Testing4.4.4.1 Self-testing Coagulation Market4.4.4.2 D-Dimer Testing4.4.5 Point of Care Coagulation Testing Assay Market and Technology Trends4.4.5.1 Point of Care Coagulation Testing Assay Market Trends4.4.5.2 Point of Care Coagulation Testing Assay Technology Trends4.4.5.3 Point of Care Coagulation Testing Assay Strategic Recommendations4.5 Rapid Cardiac Markers4.5.1 U.S. Market4.5.2 European Market4.5.3 Market Drivers and Restraints4.5.3.1 Market Drivers4.5.3.2 Market Restraints4.5.4 Point of Care Cardiac Marker Testing Assay Market and Technology Trends4.5.4.1 Point of Care Cardiac Marker Testing Assay Market Trends4.5.4.2 Point of Care Cardiac Marker Testing Assay Technology Trends4.5.4.3 Point of Care Cardiac Marker Testing Assay Strategic Recommendations4.6 Drugs of Abuse Screening Testing4.6.1 Acetaminophen4.6.2 Tricyclic Antidepressants (TCAs)4.6.3 Other Toxic Drugs4.6.4 Drug Testing Selectivity4.6.5 Methaqualone and Phencyclidine (PCP)4.6.6 Tetrahydrocannabinol4.6.7 Drug Panels by Toxidromes4.6.8 Alcohol Testing4.7 Urine Strips4.8 Pregnancy Tests4.9 Fecal Occult Blood4.10 Hemoglobin Testing
    • 4.11 Miscellaneous Rapid Tests4.11.1 Estriol4.11.2 Fetal Fibronectin (fFN)4.11.3 H. pylori4.11.4 Vaginal pH and Vaginitis4.11.5 Bladder Cancer4.11.6 Fetal Status4.11.7 Heparin-induced Thrombocytopenia4.12 Human Immunodeficiency Virus (HIV)4.13 Cholesterol4.14 Infectious Disease4.14.1 Clostridium difficile4.14.2 Giardia4.14.3 Salmonella and Campylobacter4.14.4 Malaria Testing4.14.5 Influenza Testing4.14.6 Strep Testing4.14.7 Chlamydia4.14.8 Mononucleosis4.14.9 Rubella4.14.10 Methicillin-resistant Staphylococcus aureus (MRSA)4.14.11 Hepatitis4.14.12 Gonorrhea4.14.13 Tuberculosis (TB)4.14.14 Herpes Simplex Virus Type-24.14.15 Legionella4.14.16 RSV4.14.16.1 Market Drivers and Restraints4.14.16.1.1 Market Drivers4.14.16.1.2 Market Restraints4.14.16.2 Point of Care Infectious Disease Testing Assay Market and Technology Trends4.14.16.2.1 Point of Care Infectious Disease Testing Assay Market Trends4.14.16.2.2 Point of Care Infectious Disease Testing Assay Technology Trends4.14.16.2.3 Point of Care Infectious Disease Testing Assay Strategic Recommendations4.15 Infant Jaundice4.16 Anthrax4.17 Rupture of Fetal Membranes (ROM)4.18 Food Pathogens4.19 Typhoid5. POCT: Reagents and Equipment5.1 Blood Glucose Monitoring5.1.1 LifeScan5.1.2 Roche Accu-Chek5.1.3 Abbott Diabetes Care5.1.4 HemoCue5.1.5 Stanbio/GDS Technology5.1.6 Abaxis, Inc.5.1.7 Arkray (Japan)
    • 5.1.8 Accurex (India)5.1.9 Home Diagnostics, Inc.5.1.10 Nova Biomedical5.1.11 Bayer5.1.11.1 Hemoglobin A1c Measurements5.1.12 Biosite (now part of Alere)5.1.13 Siemens Healthcare Diagnostics5.1.14 Infopia5.1.15 Diasys5.1.16 Quotient Dx5.1.17 Cholestech (Acquired by Inverness Medical Innovations, now named Alere)5.1.18 Bio-Rad5.1.19 Axis-Shield5.2 Blood Gas and Electrolytes5.2.1 Roche Corporation5.2.2 TechnoMedica5.2.3 Siemens Healthcare Diagnostics5.2.4 Instrumentation Laboratory5.2.5 Nova Biomedical5.2.6 Radiometer5.2.7 Abbott Laboratories5.2.8 Span Diagnostics5.2.9 Nexus Dx Avoximeter Systems for Co-oximetry5.2.10 ITC (Nexus Dx)5.2.11 Alere5.2.12 Abaxis, Inc.5.3 Rapid Coagulation Tests5.3.1 POC Coagulation Instrument Description5.3.1.1 Roche Diagnostics Corp.5.3.1.2 Abbott Laboratories5.3.1.3 International Technidyne Corporation Nexus DX5.3.1.4 Medtronic5.3.1.5 HemoSense (Inverness)5.3.1.6 Helena Laboratories Point of Care5.3.1.7 Sienco, Inc.5.3.1.8 Accumetrics5.3.1.9 Alere5.3.1.10 ITC5.3.2 Connectivity Issues5.3.3 Cost Benefits5.3.4 Quality Control Issues5.3.5 Certification for Point of Care Coagulation Devices5.4 Rapid Cardiac Markers5.4.1 Biosite Diagnostics (Inverness, now called Alere)5.4.2 Roche Diagnostics5.4.3 Ani Biotech5.4.4 Response Biomedical Corporation5.4.5 Siemens Healthcare Diagnostics (f/k/a Bayer Healthcare Diagnostics, DiagnosticProducts Corporation, and Dade Behring)
    • 5.4.6 Lab21 Ltd.5.4.7 Abbott Laboratories5.4.8 LifeSign (Princeton BioMediTech Corp.)5.4.9 Mitsubishi Kagaku Iatron5.4.10 Alpha Scientific5.5 Rapid Drugs of Abuse5.5.1 Biosite Diagnostics (Inverness, now called Alere)5.5.2 Abbott Diagnostics5.5.3 Roche Diagnostics5.5.4 BioScan Screening Systems, Inc.5.5.5 American Bio Medica Corp.5.5.6 Phamatech, Inc.5.5.7 First Check Medical5.5.8 OraSure5.5.9 Avitar, Inc.5.5.10 Concateno5.5.11 Pathtech5.5.12 Alfa Scientific Designs, Inc.5.5.13 TCPI, Inc.5.5.14 Roche5.5.15 Biophor Diagnostics5.6 Rapid Pregnancy and Fertility Tests5.7 Fecal Occult Blood5.7.1 Helena Laboratories5.7.2 Biomerica5.7.3 Beckman Coulter5.7.4 Worldwide Medical5.7.5 Aerscher Diagnostics5.7.6 Enterix5.7.7 Medix Biochemica5.7.8 Orion Diagnostica5.8 Hemoglobin Testing5.8.1 Wampole Laboratories5.8.2 HemoCue, Inc.5.8.3 Stanbio5.9 Miscellaneous Rapid Tests5.9.1 Triage C. difficile Panel5.9.2 Ketoacids5.9.3 Acetaminophen5.9.4 Estriol5.9.5 H. pylori5.9.6 Vaginal Fluid pH and Vaginitis5.9.7 Prostate-specific Antigen (PSA)5.9.8 Bladder Cancer5.9.9 Other Rapid Cancer Tests5.9.10 Fetal Status (PROM)5.9.11 Osteoporosis5.9.12 Hemodynamic Monitoring5.9.13 Heparin-induced Thrombocytopenia
    • 5.10 HIV5.10.1 Whole Blood, Serum or Plasma-based HIV Tests5.10.1.1 Bio-Rad Laboratories5.10.1.2 Orgenics (Inverness, now called Alere)5.10.1.3 StatSure Diagnostic Systems5.10.1.4 Trinity Biotech5.10.1.5 Savyon Diagnostics5.10.1.6 MedPharm5.10.1.7 American Bio Medica Corp.5.10.1.8 Chembio Diagnostics5.10.1.9 OraSure Technologies5.10.1.10 Inverness (Alere)5.10.2 Saliva-based HIV Tests5.10.2.1 OraSure Collection Device5.10.2.2 SureStat5.10.3 Urine-based HIV Tests5.10.3.1 MedMira Laboratories, Inc.5.10.3.2 Medical Services International, Inc.5.10.3.3 Maxim Biomedical5.10.3.4 Wampole Laboratories5.11 Cholesterol5.11.1 Cholestech (now a brand of Inverness Medical Innovations)5.11.2 Actimed Laboratories5.11.3 StatSite Meter5.11.4 Polymer Technology Systems5.11.5 PreMD, Inc. (f/k/a International Medical Innovations, Inc. [IMI])5.11.6 Abaxis, Inc.5.12 Infectious Disease5.12.1 C. difficile5.12.2 Giardia5.12.3 Dengue Fever5.12.4 Malaria Testing5.12.5 Rapid Influenza Testing5.12.6 Streptococcus Testing5.12.7 Chlamydia5.12.8 Mononucleosis5.12.9 Rubella5.12.10 Staphylococcus aureus and MRSA5.12.11 Hepatitis5.12.12 E. Coli O1575.12.13 Gonorrhea Testing5.12.14 Smallpox5.12.15 SARS5.12.16 Rabies5.12.17 Tuberculosis5.12.18 Avian Flu5.12.19 West Nile Virus5.12.20 Herpes Simplex Virus Type-25.12.21 Legionella
    • 5.12.22 RSV5.13 Infant Jaundice5.14 Anthrax5.15 Homeland Defense (Plague and Tularemia)5.16 BSE (Mad Cow Disease)5.17 Tuberculosis5.18 Typhoid5.19 Avian Flu5.20 Food Pathogens (Salmonella, Listeria, Campylobacter)5.21 Ruptured Fetal Membranes (ROM)6. POCT: Growth Regulators6.1 Moderators of Growth6.2 Personnel Acceptance6.3 Key People for POCT6.4 Information Management Issues6.4.1 Elements of Information Management for POCT: Information Processing Capabilities6.4.2 Data Mining6.4.3 Middleware6.4.4 Web Portals6.4.5 POCT-1A Standard6.5 Key Elements for POCT6.6 POCT and Reimbursement6.7 Effectiveness of Clinical Outcomes6.8 Rapid Near-Patient Testing in Hospitals6.9 Satellite Facilities6.10 Regionalization of Laboratory Care6.11 Requirements for POCT6.12 Locations of Point of Care for Patient Care6.13 Benefits of POCT6.14 Cost Elements of POCT6.15 Necessary Functions in POCT6.16 TAT for POCT6.17 Clinical Laboratory Improvement Amendments (CLIA)6.18 Sexually-transmitted Diseases in Underdeveloped Countries6.19 Sources of Error in Point of Care Testing7. Business Trends in the Point of Care Sector7.1 Sector Consolidation7.2 Diagnostic Testing Growth Trends7.2.1 Opportunities for Healthcare Stakeholders7.3 Acquisition, License Agreements, Internal Development and Partnerships7.4 Product Testing Depth in POCT7.5 Government Regulation7.5.1 U.S. Regulation7.5.1.1 Importing Medical Devices into the U.S.7.5.1.2 Exporting Medical Devices from the U.S.7.5.2 U.K. Regulation7.5.3 E.U. Regulation
    • 7.5.3.1 French Regulation7.5.4 Japanese Regulation7.5.5 Korean Regulation7.6 Increased Market Penetration7.7 Costs of doing Business in Europe7.8 Drivers of European Diagnostics Testing7.9 European Reimbursement Practices7.10 Cost Containment in Europe8. Technology Platform Innovations in POCT8.1 Sensor Systems for Diagnostic Applications8.2 Glucose Measurements8.2.1 Continuous Glucose Monitoring Systems8.3 Glucose Test Methods8.4 Cholesterol Testing8.5 The New Paradigm8.6 Consolidated Workstations and Modularity8.7 Automation and Robotics in the Clinical Laboratory8.8 Laboratory Information Systems (LIS)8.8.1 NOVIUS Lab8.9 Biosensor Technology8.10 Nanogen Third Generation Point of Care Analyzer8.11 Quidel MChip9. Data Management and Connectivity9.1 Wireless LANs9.2 Connectivity Platforms9.2.1 DataLink Data Management System9.2.2 RALS-Plus9.2.2.1 International Technidyne Corporation HEMOCHRON Signature Elite9.2.2.2 Siemens Diagnostics Rapidpoint Coag9.2.2.3 Radiometer9.2.2.4 HemoCue’s DM Hemoglobin9.2.2.5 Roche Diagnostics9.2.3 BD.id9.2.4 Medical Implant Communications Service (MICS)9.3 Advantages of POCT Connectivity9.3.1 Cost Benefit of POCT and IT Connectivity9.3.2 Hospital Network Issues10. Corporate Profiles10.1 Abaxis, Inc.10.2 Abbott Laboratories10.3 Accumetrics, Inc.10.4 AccuTech, LLC10.5 ACON Laboratories10.6 Acrongenomics10.7 Aerscher Diagnostics10.8 Akers Biosciences, Inc.
    • 10.9 Alere10.10 Alfa Scientific Designs, Inc.10.11 American Bio Medica Corporation10.12 Amic AB10.13 Ani Biotech Oy Ltd.10.14 Arkray, Inc.10.15 Atonomics A/S10.16 Audit Diagnostics10.17 Augurix Diagnostics Ltd.10.18 Axis-Shield10.19 Axxin10.20 Bayer10.21 Beckman Coulter10.22 BioLytical Laboratories10.23 Biomerica, Inc.10.24 BiOracle10.25 Bio-Rad Laboratories, Inc.10.26 BioScan Screening Systems, Inc.10.27 BioSite10.28 Calmark Sweden AB10.29 Calypte Biomedical Corporation10.30 Chembio Diagnostic Systems10.31 Chempaq A/S10.32 Cholestech10.33 Claros Diagnostics10.34 Concateno Plc10.35 Dexcom10.36 Enigma Diagnostics Ltd.10.37 Epinex Diagnostics10.38 Eurotrol10.39 Exalenz Bioscience10.40 GenBio10.41 Genzyme10.42 Helena Laboratories10.43 HemoCue AB10.44 HemoSense10.45 Home Diagnostics (Nipro Diagnostics)10.46 IND Diagnostic10.47 Instrumentation Laboratory Company10.48 ITC (International Technidyne Corporation)10.49 Jant Pharmacal Corporation10.50 Johnson & Johnson10.51 Lein Applied Diagnostics10.52 LifeAssays AB10.53 LifeSign10.54 Medica10.55 Medical Automation Systems10.56 Mediwatch10.57 Medix Biochemica
    • 10.58 MedMira10.59 MELA Sciences (formerly Electro-Optical Sciences)10.60 Meretek Diagnostics Group10.61 Meridian Bioscience10.62 Micronics10.63 3M10.64 New Horizons Diagnostics10.65 Nexus DX/ITC10.66 Nova Biomedical10.67 OraSure Technologies10.68 Orion Diagnostica10.69 Polymer Technology Systems10.70 Prima Biomedical Company10.71 QBC Diagnostics10.72 Qualigen10.73 Quidel10.74 Radiometer Medical10.75 Response Biomedical10.76 Roche10.77 Telcor10.78 SA Scientific10.79 Siemens AG10.80 Stanbio Laboratory11. POCT Sector Trends and Forecasts11.1 Home Care Analysis as Part of Near-Patient Testing11.2 Non-Traditional Collection for POCT11.3 New Systems for Critical Care and Near-Patient Testing11.4 Utility of Near-Patient Testing in Critical Care Settings11.5 Physician’s Office Market11.6 Information Management Advances11.7 Test-Ordering Patterns and Demand for POCT11.8 Demand for Emergency Department Services11.9 Move Away from Central Laboratory11.10 Healthcare Cost Controls11.11 M&A in POCT11.12 Competition for Services11.13 Drivers of POCT11.14 Confluence of New Technology11.15 Difficulties of Design for Point of Care Products11.16 European Hospital Structure11.17 The Biggest New Opportunities in POCT12. Corporate DirectoryLIST OF FIGURESFigure 3.1: Blood Tests Ordered in Emergency Department VisitsFigure 3.2: Worldwide Distribution of IVD Testing, 2010Figure 3.3: Global Point of Care Revenues, 2005-2012
    • Figure 3.4: Global Growth of Point of Care Testing Volume, 2000-2012Figure 3.5: Global POCT Share of Total IVD Testing Market, 2010Figure 4.1: Number of HbA1c Tests Performed Globally as POCT, 1991-2006Figure 4.2: Percentage of Visits for Influenza-like Illness (ILI) Reported by the U.S.Outpatient Influenza-like Illness Surveillance Network (ILINet) and Weekly NationalSummary, September 30, 2007-February 12, 2011Figure 4.3: Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS CollaboratingLaboratories, National Summary, 2010-2011Figure 5.1: Global POCT Share of HIV Testing Market, 2008Figure 6.1: Annual Rate of Emergency Room Visits by Primary Expected Source of PaymentFigure 6.2: CLIA Laboratories by Certificate TypesLIST OF TABLESTable 2.1: Percentage of POCT Performed in Selected HospitalsTable 2.2: POCT Procedural Advantages for Hospital TestingTable 2.3: POCT TrendsTable 2.4: Professional POCT Compared to Home TestingTable 2.5: Drivers for Integrating POCT into Hospital RoutinesTable 3.1: Actual Reported Number of ER Visits in U.S. Hospitals, 1997-2010Table 3.2: Number of Point of Care Tests in the U.S., 2000-2012Table 3.3: Global Clinical Laboratory Market Sales, 1998-2011Table 3.4: Overall IVD Testing Market Worldwide, 2010Table 3.5: Worldwide Distribution of IVD Testing, 2010Table 3.6: Top 12 Country IVD Testing Markets, 2010Table 3.7: Global Point of Care Revenues, 2005-2012Table 3.8: Worldwide POCT Market Size by Geographic Location, 2005-2012Table 3.9: Worldwide Distribution of POCT, 2010Table 3.10: Worldwide Clinical Diagnostic POCT and Rapid Test Market Segments, 2010Table 3.11: Worldwide POCT by Performance Location, 2010Table 3.12: Largest POCT Diagnostic Companies Worldwide, 2010Table 3.13: U.S. Clinical Laboratory Testing Market, 2003-2012Table 3.14: U.S. Clinical Laboratory Diagnostic Test Market Segments by Location ofAnalysis, 2010Table 3.15: U.S. POCT Market, 2000-2012Table 3.16: U.S. POCT by Performance Location, 2010Table 3.17: U.S. Clinical Diagnostic POCT and Rapid Test Market Segments, 2010Table 3.18: European Clinical Laboratory Testing IVD Reagents and Instruments Market inDollars, 2000-2012Table 3.19: European Clinical Laboratory Testing IVD Reagents and Instruments Market inEuros, 2000-2012Table 3.20: European Clinical Laboratory Testing Diagnostics by Country Market Estimates,2010Table 3.21: European Rapid POCT by Country Market Estimates, 2010Table 3.22: Regional Comparison of Healthcare Spending for IVD for Eastern EuropeTable 3.23: European POCT Market, 2005-2012Table 3.24: Top 12 POCT Country Markets, 2010Table 3.25: German Clinical Laboratory Testing Diagnostics Products Market Sales, 2003-2012Table 3.26: German POCT Diagnostics Products Market Sales, 2003-2012
    • Table 3.27: German Clinical Diagnostic Rapid Test Market Segments, 2010Table 3.28: U.K. Clinical Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.29: U.K. POCT Diagnostics Products Market Sales, 2006-2012Table 3.30: U.K. Clinical Diagnostic Rapid Test Market Segments, 2010Table 3.31: Major U.K. IVD ManufacturersTable 3.32: U.S. IVD Manufacturers Doing Business in the U.K.Table 3.33: Other European Companies that Manufacture IVD Products in the U.K.Table 3.34: French Clinical IVD Testing Diagnostics Products Market Sales, 2003-2012Table 3.35: French POCT Diagnostics Products Market Sales, 2005-2012Table 3.36: French Clinical Diagnostic Rapid Test Market Segments, 2010Table 3.37: Italian Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.38: Italian POCT Diagnostics Products Market Sales, 2005-2012Table 3.39: Italian Clinical Diagnostic Rapid Test Market Segments, 2010Table 3.40: Spanish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.41: Spanish Clinical Diagnostic Rapid Test Market Segments, 2010Table 3.42: Spanish POCT Diagnostics Products Market Sales, 2005-2012Table 3.43: Scandinavian POCT Diagnostics Products Market Sales, 2000-2012Table 3.44: Swedish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.45: Swedish POCT Diagnostics Products Market Sales, 2005-2012Table 3.46: Finnish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.47: Finnish POCT Diagnostics Products Market Sales, 2005-2012Table 3.48: Norwegian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.49: Norwegian POCT Diagnostics Products Market Sales, 2005-2012Table 3.50: Swiss Clinical Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.51: Swiss POCT Diagnostics Products Market Sales, 2005-2012Table 3.52: Dutch Clinical Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.53: Dutch POCT Diagnostics Products Market Sales, 2005-2012Table 3.54: Belgian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.55: Belgian POCT Diagnostics Products Market Sales, 2005-2012Table 3.56: Portuguese Clinical Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.57: Portuguese POCT Diagnostics Products Market Sales, 2005-2012Table 3.58: Austrian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.59: Austrian POCT Diagnostics Products Market Sales, 2005-2012Table 3.60: Greek Clinical Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.61: Greek POCT Diagnostics Products Market Sales, 2005-2012Table 3.62: Polish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012Table 3.63: Polish POCT Diagnostics Products Market Sales, 2005-2012Table 3.64: Czech Clinical Laboratory Diagnostics Products Market Sales, 2004-2012Table 3.65: Czech POCT Diagnostics Products Market Sales, 2005-2012Table 3.66: Turkish POCT Market, 2000-2012Table 3.67: Japanese POCT Market, 2000-2012Table 3.68: Japanese Population and Aging Demographics Forecast, 2000-2050Table 3.69: Indian IVD Market for Instruments and Reagents, 2004-2012Table 3.70: Number of Automated Clinical Labs in India, 2004-2012Table 3.71: Indian IVD Market, 2010Table 3.72: Indian POCT Diagnostics Products Market Sales, 2000-2012Table 3.73: Chinese IVD Market, 2006-2012Table 3.74: Number of Automated Clinical Labs in China, 2004-2012Table 3.75: Chinese IVD Market, 2010
    • Table 3.76: Chinese POCT Diagnostics Products Market Sales, 2000-2012Table 3.77: Rest of the World POCT Market, 2000-2012Table 3.78: Canadian POCT Market, 2000-2012Table 3.79: Brazilian POCT Market, 2000-2012Table 3.80: Australian POCT Market, 2000-2012Table 4.1: World Market Share of Point of Care Glucose Monitoring MarketersTable 4.2: Global Population of Persons with Diabetes, 1995 and 2025Table 4.3: Professional Glucose Testing Market for POCT Worldwide Revenue and Forecasts,2001-2012Table 4.4: U.S. Point of Care Glucose Testing Market, 1997-2012Table 4.5: Rapid Testing U.S. Market Share for Blood Glucose Testing SegmentTable 4.6: HbA1c Testing Market for POCT Worldwide, 2006-2012Table 4.7: Point of Care Glucose Testing Market: Market Drivers Ranked in Order of ImpactTable 4.8: Point of Care Glucose Testing Market: Market Restraints Ranked in Order ofImpactTable 4.9: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threatsof the Glucose Point of Care MarketTable 4.10: Critical Care Blood Gas Testing Market for POCT Worldwide, 2006-2012Table 4.11: Blood Gas and Electrolyte Market for POCT in the U.S., 2001-2012Table 4.12: Location Market Share of Critical Care Blood Gas Testing, 1990 and 2010Table 4.13: Manufacturer Market Share U.S. POCT Blood Gas and Electrolytes Market, 2010Table 4.14: Hospital Locations of Point of Care Coagulation TestingTable 4.15: Drivers for Point of Care Coagulation TestingTable 4.16: Barriers for Point of Care Coagulation TestingTable 4.17: Coagulation Testing Market for POCT Worldwide, 2006-2012Table 4.18: Handheld Coagulation Testing Market for POCT Worldwide, 2006-2012Table 4.19: Coagulation Market for POCT in the U.S., 2001-2015Table 4.20: Point of Care Prothrombin Market for POCT in the U.S., 2000-2010Table 4.21: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threatsof the Coagulation Point of Care MarketTable 4.22: Cardiac Marker Market for POCT in the U.S., 2001-2016Table 4.23: Cardiac Marker Market for POCT Worldwide, 2001-2016Table 4.24: Manufacturer Market Share U.S. POCT Cardiac Marker Market, 2010Table 4.25: Cardiac Marker Market for POCT in Europe, 2008-2016Table 4.26: Point of Care Cardiac Marker Testing Market: Market Drivers Ranked in Order ofImpactTable 4.27: Point of Care Cardiac Marker Testing Market: Market Restraints Ranked in Orderof ImpactTable 4.28: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threatsof the Cardiac Marker Point of Care MarketTable 4.29: Drugs of Abuse Testing Market for POCT Worldwide, 2006-2015Table 4.30: U.S. Point of Care Drugs of Abuse Testing Market, 2006-2015Table 4.31: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency DepartmentTable 4.32: Stat Urine Testing Drug RecommendationsTable 4.33: Device Specifications for POCT Breath Alcohol AnalysisTable 4.34: Global Point of Care Urine Test Strip Testing Market, 2001-2010Table 4.35: Global Point of Care Urine Test Strip POCT Testing Market, 2006-2012Table 4.36: U.S. Point of Care Urine Test Strip Testing Market, 2001-2011Table 4.37: U.S. Point of Care Urine Test Strip Testing Market Share
    • Table 4.38: Medicare Fee Schedule for Urine Chemistry Testing,Table 4.39: Pregnancy Testing Market for POCT Worldwide, 2006-2012Table 4.40: U.S. Point of Care Pregnancy Testing Market, 2001-2012Table 4.41: U.S. Market Share for Rapid Point of Care Pregnancy TestsTable 4.42: Hemoglobin Testing Market for POCT Worldwide, 2006-2012Table 4.43: Drivers of Demand for HIV TestingTable 4.44: Worldwide POCT Market for HIV, 2001-2012Table 4.45: U.S. POCT Market for HIV, 2001-2012Table 4.46: Countries with the Highest Prevalence of HIV/AIDSTable 4.47: FDA-approved Rapid HIV Antibody Screening TestsTable 4.48: Cholesterol Testing Market for POCT Worldwide, 2006-2012Table 4.49: Infectious Disease Testing Market for POCT Worldwide, 2006-2012Table 4.50: Worldwide Point of Care Influenza Testing Market, 2002-2010Table 4.51: U.S. Point of Care Influenza Testing Market, 2002-2010Table 4.52: U.S. Market Share for Rapid Point of Care Influenza Tests, 2010Table 4.53: Worldwide Point of Care Strep A Testing Market, 2002-2010Table 4.54: U.S. Point of Care Strep A Testing Market, 2002-2010Table 4.55: U.S. Market Share for Rapid Point of Care for Group A Strep TestsTable 4.56: Global Market for Chlamydia Diagnostic Testing, 2000-2010Table 4.57: U.S. Market for Chlamydia Diagnostic Testing, 2000-2010Table 4.58: U.S. Market for MRSA Rapid Testing, 2006-2013Table 4.59: Global Market for Gonorrhea Diagnostic Testing, 2000-2010Table 4.60: Global Market for TB Diagnostic Testing, 2000-2010Table 4.61: Point of Care Infectious Disease Testing Market: Market Drivers Ranked in Orderof ImpactTable 4.62: Point of Care Infectious Disease Testing Market: Market Restraints Ranked inOrder of ImpactTable 4.63: U.S. Anthrax Test MarketTable 5.1: Roche Diagnostics Glucose Testing ProductsTable 5.2: Largest U.S. POCT Coagulation Diagnostic Testing Companies, 2010Table 5.3: Actalyke XLTable 5.4: Actalyke MiniTable 5.5: Drug Test Sensitivity Cut-Off Levels Set by NIDA, WHO and SAMHSA for Drugs ofAbuseTable 5.6: Major Competitors in the Drugs of Abuse Oral Testing Market SegmentTable 5.7: Major Competitors in the Drugs of Abuse Urine Testing Market SegmentTable 5.8: ColoCARE Fecal Occult Blood TestTable 5.9: Competitive Factors Related to HIV TestsTable 5.10: Largest POCT Diagnostic Companies Worldwide, 2008Table 5.11: Influenza Diagnostic Rapid TestsTable 5.12: Type of Hepatitis Test: Lateral FlowTable 5.13: Flow-throughTable 5.14: AgglutinationTable 5.15: ImmunoblotTable 5.16: AmniSureTable 6.1: Access PointsTable 6.2: Desktop Adapters—Four ComputersTable 6.3: Desktop Adapters—One ComputerTable 6.4: PCMCIA Adapters
    • Table 6.5: POCT1-Compliant Connectivity Point of Care InstrumentsTable 6.6: POCT Clinical Outcomes in Diabetic KetoacidosisTable 6.7: POCT Clinical Outcomes in Arterial Blood Gas MeasurementsTable 6.8: POCT in Three Hospitals—Cost Analysis with Labor IncludedTable 6.9: POCT versus Central Lab—Cost Analysis for Glucose TestingTable 6.10: CLIA Laboratories by Type of FacilityTable 6.11: Financial Comparison for Moderate and Waived CLIA LabsTable 6.12: Top Ten CMS Survey Deficiencies for CLIA LaboratoriesTable 7.1: Key Changes in IVD Business StructureTable 7.2: Business Trends in POCTTable 7.3: Key Players Bring Business Developments to Point of Care Diagnostic TestingTable 7.4: Emerging Trends in Point of Care TestingTable 7.5: Future Developments in Point of Care TestingTable 7.6: The Confluence of the New TechnologyTable 7.7: Professional Continuous Glucose Monitoring (CGM) ICD-9 CodesTable 7.8: Professional CGMTable 8.1: Normal Glucose Values—Fasting StateTable 9.1: Applications for Wireless LAN TechnologyTable 9.2: Customized Reports Must Support CAP and JCAHO RequirementsTable 9.3: RALS-Plus Point of Care Market ShareTable 9.4: Applications of RALS Connectivity with POCT DevicesTable 10.1: Abaxis Blood Analysis Diagnostic TestsTable 10.2: Reagent Discs Offered with the Piccolo Chemistry AnalyzersTable 10.3: Products Marketed by Abbott in the Diagnostic MarketTable 11.1: Improvements in Achieving ED Operational Efficiency Using POCTTable 11.2: Test Menu and TAT for EDTable 11.3: Top Reasons Why Point of Care Cardiac Marker Testing is Implemented in theEDTable 11.4: Key Areas and Metrics that Hospitals Measure to Assess Efficiency of EDTable 11.5: Estimates of Patient Costs by DRGLatest Market Research Reports:Cancer Diagnostic Testing World MarketsCompanion Diagnostics in Personalized Medicine and Cancer TherapyMolecular Diagnostics in Cancer TestingMolecular Diagnostics MarketsPoint of Care Diagnostic Testing World MarketsPositron Emission Tomography (PET) MarketsAbout Us:ReportsnReports is an online library of over 75,000 market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
    • Contact:Mr. Priyank7557 Rambler road,Suite 727, Dallas, TX 75231Tel: +1-888-989-8004 EXT 106E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comBlog: http://www.reportsnreportsblog.com